“These exciting data from MATTERHORN show that a durvalumab-based perioperative regimen resulted in a clinically ... it was found that durvalumab plus neoadjuvant FLOT chemotherapy improved ...

This perioperative approach with Imfinzi underscores our commitment to moving into earlier stages of cancer where novel therapies can have the biggest impact on patients’ liv ...

The trial evaluated this regimen versus perioperative chemotherapy ... The safety profile for Imfinzi and FLOT chemotherapy was consistent with the known profiles of each medicine, and there ...

When added to a chemotherapy combination called FLOT, Imfinzi significantly reduced ... and gastroesophageal junction cancers who got the regimen before and after surgery, the company said Friday.